Research progress on PD-1/PD-L1 resistance mechanism and combination therapy
10.16571/j.cnki.1008-8199.2020.03.018
- VernacularTitle: PD-1/PD-L1耐药机制及联合治疗的研究进展
- Author:
Yuan-yuan SUN
1
;
Ming-zhi ZHANG
1
Author Information
1. Department of Oncology, the First Affiliated Hospital of Zhengzhou University, Zhengzhou 450001, Henan,China
- Publication Type:Journal Article
- Keywords:
PD-1；PD-L1；resistance mechanism；combination therapy
- From:
Journal of Medical Postgraduates
2020;33(3):312-316
- CountryChina
- Language:Chinese
-
Abstract:
PD-1/PD-L1 plays a pivotal role in the inhibition of T lymphocytes and tumor immune escape. Immunological checkpoint inhibitors of PD-1/PD-L1 can restore inactivated T cells and enhance the ability of killing tumor cell. At present, PD-1/PD-L1 inhibitors have been used in a variety of tumor types. Although some patients prove significant effects, there are still some patients with primary or acquired resistance to PD-1/PD-L1 inhibitors. The mechanism of resistance is related to the loss of the first signal or costimulatory signal, the expression of PD-1/PD-L1,the expression of other immune checkpoints on the surface of T cells, the immunosuppressive tumor microenvironment and systemic immunity. And we will find ways to prolong the survival time of patients through the combination therapy. This article mainly reviews the resistance mechanism and combination therapy of PD-1/PD-L1.
